Targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy | Science

Cardiac fibrosis independently predicts adverse outcomes in heart failure (HF), yet no Food and Drug Administration–approved therapy directly targets fibrotic remodeling in the heart. To address this unmet clinical need, we used a multidimensional drug ...
Newsletter
Get the latest news delivered to your inbox.
Related articles





